Currently available DYRK1A inhibitors such as epigallocatechin gallate (EGCG) derived from green tea or harmine, a hallucinogenic alkaloid, have shown a preliminary reduction in neurodevelopmental abnormalities across various animal models of DS and some human trials (Guedj et al., 2009; Adayev et al., 2011; Jarhad et al., 2018). Here, DYRK1A is linked to Dravet syndrome.